Typicality: | 0.313 |
Saliency: | 0.338 |
in certain cancers | 6 | location |
in crohn’s disease | 3 | location |
to naltrexone | 2 | other |
drug → stop → the progression of the disease | 11 |
drug → stop → disease progression | 6 |
drug → halt → the progression of the disease | 5 |
drug → prevent → disease progression | 4 |
drug → be shown to halt → disease progression | 3 |
drug → prevent → the progression of the disease | 3 |
drug → control → disease progression | 3 |
drug → halt → progression of the disease | 3 |
negative | neutral | positive |
0.213 | 0.540 | 0.247 |
Raw frequency | 38 |
Normalized frequency | 0.338 |
Modifier score | 0.250 |
Perplexity | 22.499 |